Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL4601512 | 1.00 | SLC34A1 (0.73) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL28894407 | 1.00 | SLC34A1 (0.73) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL724055 | 1.00 | SLC34A1 (0.73) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL28979871 | 1.00 | SLC34A1 (0.73) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL101070 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL653726 | 1.00 | SLC34A1 (0.73) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL40491 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL4731817 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL8972786 | 1.00 | SLC34A1 (0.73) | SLC34A1KDM4ECYP2C19KMT2ALMNA | |
| Phosphoric Acid SCHEMBL23091295 | 0.95 | SLC34A1 (0.67) | SLC34A1KDM4ECYP2C19KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113613721-A | NLRP modulators | 诺华股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-113329998-A | Sulfonimidyl amide compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-113316566-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-08-27 | — | — | CN | disclosed |
| CN-113286784-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| CN-113227055-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-113166081-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166065-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113015730-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-06-22 | — | — | CN | disclosed |
| CN-112654350-A | Methods of treating a subject resistant to a TNF inhibitor or selecting a treatment for said subject using an NLRP3 antagonist | 诺华股份有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-112584899-A | NLRP modulators | 诺华股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-111094243-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华炎症研究公司 | 2020-05-01 | — | — | CN | disclosed |
| CN-111094242-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华炎症研究公司 | 2020-05-01 | — | — | CN | disclosed |
| US-9844530-B1 | Ophthalmic solutions for glaucoma and conjunctivitis treatment | Axim Biotechnologies, Inc. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9814695-B2 | Ophthalmic solutions for glaucoma and conjunctivitis treatment | Axim Biotechnologies, Inc. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-3240535-A1 | OPHTHALMIC SOLUTIONS FOR GLAUCOMA AND CONJUNCTIVITIS TREATMENT | Axim Biotechnologies, Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109531-A1 | OPHTHALMIC SOLUTIONS FOR GLAUCOMA AND CONJUNCTIVITIS TREATMENT | Axim Biotechnologies, Inc. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160184259-A1 | OPHTHALMIC SOLUTIONS FOR GLAUCOMA AND CONJUNCTIVITIS TREATMENT | APIRX PHARMACEUTICAL USA, LLC | 2016-06-30 | — | — | US | disclosed |
| EP-2559339-A1 | DISINFECTION AID FOR OZONE DISINFECTION AND METHOD FOR OZONE DISINFECTION | Lion Corporation (JP) | 2013-02-20 | — | — | EP | disclosed |
| US-20130028787-A1 | STERILIZATION AUXILIARY FOR OZONE STERILIZATION AND OZONE STERILIZATION METHOD | LION CORPORATION (JP) | 2013-01-31 | — | — | US | disclosed |